The science is in question.
A 30,000 page IND that took months and months to get through with caveats by the FDA.
2 years of PAR doing non-clinical studies in the background and a failed dosing study results in very very lukewarm reception by the FDA.
TGA provisional approval gate should have been by now - so why the radio silence. The timeframe should be 30 days from submission at this checkpoint - a submission they delayed for four years.
and if you think that’s bad - a fund management firm that has no experience in pharma is now hired as their business development consultant to get them out of this mess.
Where we at?, page-666
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $101.4M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 30.0¢ | 29.0¢ | $40.16K | 137.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 66491 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 33118 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |